Loading...
Market
What will be the consensus analyst rating for Organon by end of 2024?
2
Resolution / Starting Odds
Strong Buy • 25%
Buy • 25%
Hold • 25%
Sell • 25%
Analyst reports from financial institutions like Morgan Stanley, Goldman Sachs
Story
Organon to Acquire Dermavant for Up to $1.2 Billion with $175 Million Upfront
Sep 18, 2024, 01:15 PM
Organon has announced its acquisition of Dermavant Sciences, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The terms of the deal involve an upfront payment of $175 million, with additional payments contingent on regulatory approval and sales milestones, potentially reaching a total of $1.2 billion. This includes $75 million on approval in AtD. Roivant's stock rose by 2.2% pre-market following the announcement. This strategic move is seen as positive for Roivant, while analysts have mixed opinions on its impact on Organon.
View original story
Similar markets
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Less than $25 • 25%
$25 to $29.99 • 25%
$30 to $34.99 • 25%
$35 or more • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Below $900 • 25%
$900 to $950 • 25%
$950 to $1000 • 25%
Above $1000 • 25%
Yes • 50%
No • 50%
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%